Icosapent Ethyl

Icosapent ethyl significantly reduced coronary events and led to numerically fewer CV events at 5 years for patients with CAD and low plasma eicosapentaenoic acid already taking statin therapy, researchers reported.

PHILADELPHIA — In this Healio video exclusive, Deepak L. Bhatt, MD, MPH, discusses two hot topics in cardiometabolic medicine: icosapent ethyl and sotagliflozin.

In statin-treated patients with CAD and elevated triglycerides, icosapent ethyl benefited coronary physiology as assessed by CT-derived fractional flow reserve compared with placebo, according to new data from the EVAPORATE trial.

NEW ORLEANS — In patients with elevated triglycerides and recent ACS, icosapent ethyl reduced risk for first and total ischemic events compared with placebo, according to new data from the REDUCE-IT trial.

In current and former smokers, treatment with icosapent ethyl reduced CV event risk to levels observed in never smokers, according to new data from REDUCE-IT presented at the European Society of Cardiology Congress.

The National Lipid Association updated its scientific statement on statin intolerance with a revised definition of statin intolerance and new guidance on how to manage patients with true or partial statin intolerance.

A medical team in Maryland successfully transplanted a genetically modified pig heart into a human for the first time in history.

In a new analysis of the REDUCE-IT trial, the treatment effect of icosapent ethyl was consistent across different agents and categories of statins patients were taking.

The American Heart Association Scientific Sessions were held virtually Nov. 13 to 15. The event included numerous presentations of new data in cardiology.